Search Results
Sep 16, 2025, 15:06 ET Parker Waichman LLP Files Lawsuit on Behalf of Baltimore Resident Alleging Irreversible Eye Condition After Taking Ozempic
individual who developed non-arteritic anterior ischemic optic neuropathy (NAION) after taking Ozempic, a widely prescribed GLP-1 receptor agonist. The latest case, Christensen v. Novo Nordisk Inc., Docket No. MID-L-0056489-25, was filed September
More news about: Parker Waichman LLP
Sep 16, 2025, 09:14 ET Nutrium Raises $12 million in Series A Funding Round Led by Vesalius Biocapital
costs.The timing of the capital infusion is especially notable as soaring healthcare costs driven by obesity and the growing demand for GLP-1 medications make sustainable, expert-led non-pharmaceutical wellness solutions that improve health outcomes essential for employers and executives.
More news about: Nutrium
Sep 16, 2025, 08:45 ET Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo's branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo's capability to penetrate said markets
More news about: Levi & Korsinsky, LLP
Sep 16, 2025, 08:42 ET Navion Launches Pharmacy Partner Portal to Empower Clients with Marketing, Education, and Growth Solutions
sheets aligned with pharmacy benefit and cost-containment prioritiesTimely pharmacy insights tied to current trends like GLP-1 managementSharable FAQs that translate complex concepts into clear group-ready explanationsRegularly refreshed content
More news about: Navion
Sep 16, 2025, 08:14 ET Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History
the U.S.HT-KIT: Achieving Preclinical MilestonesThe Company successfully completed the Good Laboratory Practice (GLP) bioanalytical phase for HT-KIT, exceeding internationally recognized regulatory thresholds. This achievement supports advancement into formal toxicology
More news about: Hoth Therapeutics, Inc.
Sep 16, 2025, 08:00 ET Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model
by persistent inflammation. GLP-1 receptor agonists (GLP-1RAs) also module immune responses, with both myeloid cells and Tregs expressing a high density of GLP-1 receptors. Our prior in vitro studies showed that combining LD IL-2 with a GLP-1RA synergistically enhances Treg
More news about: Coya Therapeutics, Inc.
Sep 16, 2025, 04:46 ET New Scientific Review Highlights β-Lactoglobulin's Dual Benefits for Metabolic and Muscle Health
have been shown to support glucose regulation. Together, these properties underpin BLG's comprehensive metabolic actions – influencing insulin, GIP, GLP-1, and glucagon, supporting glucose uptake, slowing gastric emptying, and promoting satiety – and help create a favorable hormonal milieu that stimulates
More news about: 21st.Bio
Sep 16, 2025, 04:42 ET New Scientific Review Highlights β-Lactoglobulin's Dual Benefits for Metabolic and Muscle Health
shown to support glucose regulation. Together, these properties underpin BLG's comprehensive metabolic actions – influencing insulin, GIP, GLP-1, and glucagon, supporting glucose uptake, slowing gastric emptying, and promoting satiety – and help create a favorable hormonal milieu that stimulates
More news about: 21st.Bio
Sep 15, 2025, 09:30 ET HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor
developed for obesity. BGE-102 has demonstrated significant weight loss in preclinical models both as monotherapy and in combination with GLP-1 receptor agonists. A Phase 1 SAD/MAD trial of BGE-102 is underway, with initial SAD data anticipated by end of year. The Company is also developing
More news about: HitGen Inc.
Sep 15, 2025, 08:45 ET Investors who lost money on Novo Nordisk A/S(NVO) should contact The Gross Law Firm about pending Class Action - NVO
impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo's branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo's capability to penetrate said markets
More news about: The Gross Law Firm
Sep 15, 2025, 08:00 ET Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity
management. " Stella Shi, CEO, added, "RN3161 could maintain high quality weight loss post GLP-1 era. This milestone reflects our ambition to reshape the obesity treatment paradigm for healthier weight loss. It renews our mission to bring innovative
More news about: Rona Therapeutics
Sep 15, 2025, 08:00 ET Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity
obesity management. " Stella Shi, CEO, added, "RN3161 could maintain high quality weight loss post GLP-1 era. This milestone reflects our ambition to reshape the obesity treatment paradigm for healthier weight loss. It renews our mission to bring innovative
More news about: Rona Therapeutics
Sep 15, 2025, 05:43 ET eDrugstore Teams Up With PeakBody and Peter Camillo to Expand Performance and Wellness Offerings
GHRHs: Harnessing growth hormone and its secretagogues to stimulate muscle growth, enhance recovery, and slow down age-related decline.GLP-1 Agonists: Powerful tools for appetite control, weight loss, and improving metabolic health.Recovery Peptides such as BPC-157: Known
More news about: eDrugstore